A new study highlights the risks of nutritional deficiencies in children taking weight-loss drugs like Ozempic and Zepbound. About 1 in 6 kids prescribed GLP-1 medications develop a nutritional health problem within a year, according to the research.
The study, published in the journal Childhood Obesity, found that vitamin D deficiency was the most common issue, affecting more than 12% of children within a year of starting treatment. Anemia was also a concern, with nutritional anemia and iron-deficiency anemia each impacting around 1.4% to 1.6% of kids.
GLP-1 Drugs and Childhood Obesity
GLP-1 drugs mimic a hormone that helps control insulin, blood sugar, decreases appetite, and slows digestion of food. While these medications can be effective in treating childhood obesity, researchers are concerned that the reduced appetite caused by GLP-1 drugs might lead to nutritional deficiencies.
The study analyzed insurance claims data from 2017 to 2022, identifying over 2,000 children aged 10 to 17 who were prescribed a GLP-1 drug. On average, these children were 15 years old, and nearly 63% had an obesity diagnosis.
Nutritional Counseling Lacking
Despite the risks, the study found that few children received nutritional counseling after starting GLP-1 treatment. Only 5% of patients received counseling within 30 days, and fewer than 25% received it within 6 months.
Justin Ryder, senior author of the study and vice chair of research at Ann & Robert H. Lurie Children’s Hospital of Chicago, emphasized the need for proactive nutritional management.
For families, this means ensuring children on these medications receive proper nutritional support.
Long-Term Implications
Nutrients like vitamin D, iron, and calcium are of particular concern during adolescence, when deficiencies may have lasting implications for skeletal health and overall development. The study shows the need for better monitoring and support to ensure children on GLP-1 drugs grow healthily.
Parents of children taking these medications should prioritize nutritional counseling to meet their child’s developmental needs. As GLP-1 use becomes more common in pediatric care, addressing these risks will be key for safe and effective treatment.